Journal Article
. 2007 Jul;3(4).
doi: 10.1200/JOP.0742001.

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

Ruth Oratz 1 Dev Paul  Allen L Cohn  Scot M Sedlacek  
Affiliations
  • PMID: 20859407
  •     7 References
  •     41 citations

Abstract

Purpose: To investigate whether recurrence score (RS) as determined using a commercial reference laboratory test influences clinicians' treatment recommendations and eventual treatment in patients with early-stage breast cancer.

Methods: A retrospective analysis was performed on 74 patients from a community-based oncology practice with estrogen receptor (ER) -positive, lymph node (LN) -negative stage I or II breast cancer for which RS was obtained. Demographic and pathology information was extracted from medical records. Ten-year relapse-free survival was calculated using Adjuvant! Online. Treatment recommendations before the RS knowledge were compared with treatment recommendations after RS knowledge and to the treatment eventually administered.

Results And Conclusion: A weak correlation was found between RS and both patient age and tumor size, modest correlation between RS and tumor grade, and modest correlation between RS and 10-year recurrence as determined by Adjuvant! Online. For 21% and 25% of patients, knowledge of the RS changed the clinicians' treatment recommendations and eventual treatment, respectively. The decision to change from hormone therapy to chemotherapy (with or without hormone therapy) was generally associated with high RS (high distant recurrence risk as determined by the commercial reference laboratory test), whereas the decision to change from chemotherapy to hormone therapy was generally associated with low RS (low distant recurrence risk as determined by the commercial reference laboratory test). Knowledge of the RS changed treatment recommendations and eventual treatment in patients with ER-positive/LN-negative early-stage breast cancer. Use of genomic-based prognosis may result in more accurate estimates of true recurrence risk than currently possible with commonly used prognostic factors (such as patient age, tumor size, and tumor grade) alone and thus lead to an increase in appropriate adjuvant therapy decision making.

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
John Hornberger, Leon E Cosler, Gary H Lyman.
Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Histological grading of breast carcinomas: a study of interobserver agreement.
P Robbins, S Pinder, +5 authors, C Elston.
Hum Pathol, 1995 Aug 01; 26(8). PMID: 7635449
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials.
Betty A Mincey, Frances M Palmieri, Edith A Perez.
Oncologist, 2002 Jun 18; 7(3). PMID: 12065798
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Emer O Hanrahan, Vicente Valero, Ana M Gonzalez-Angulo, Gabriel N Hortobagyi.
J Clin Oncol, 2006 May 02; 24(13). PMID: 16648513
Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Review of the clinical studies using the 21-gene assay.
Catherine M Kelly, Ellen Warner, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421266    Free PMC article.
Review.
Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer.
Gary H Lyman.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859408    Free PMC article.
Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Kim M Clark-Langone, Chithra Sangli, Jayadevi Krishnakumar, Drew Watson.
BMC Cancer, 2010 Dec 24; 10. PMID: 21176237    Free PMC article.
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.
Julia R Trosman, Stephanie L Van Bebber, Kathryn A Phillips.
J Oncol Pract, 2011 Jan 05; 6(5). PMID: 21197187    Free PMC article.
Measuring the performance of markers for guiding treatment decisions.
Holly Janes, Margaret S Pepe, Patrick M Bossuyt, William E Barlow.
Ann Intern Med, 2011 Feb 16; 154(4). PMID: 21320940    Free PMC article.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
John Hornberger, Rebecca Chien, Katie Krebs, Louis Hochheiser.
J Oncol Pract, 2011 Sep 03; 7(3 Suppl). PMID: 21886510    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
Fabien Reyal, Marc A Bollet, +9 authors, Xavier Sastre-Garau.
PLoS One, 2012 Apr 25; 7(4). PMID: 22529987    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer.
J Behav Med, 2012 Aug 11; 36(6). PMID: 22878783    Free PMC article.
Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.
Nadiyah Sulayman, Elizabeth Spellman, +4 authors, Suzanne C O'Neill.
J Cancer Epidemiol, 2012 Aug 18; 2012. PMID: 22899924    Free PMC article.
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting.
Teri L Malo, Isaac Lipkus, +3 authors, Susan T Vadaparampil.
J Cancer Epidemiol, 2012 Aug 29; 2012. PMID: 22927848    Free PMC article.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman.
Genet Med, 2012 Sep 15; 15(3). PMID: 22975761    Free PMC article.
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
BMC Cancer, 2012 Oct 04; 12. PMID: 23031196    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.
Fiona A Miller, Robin Z Hayeems, +10 authors, Lillian L Siu.
Eur J Hum Genet, 2013 Jul 19; 22(3). PMID: 23860039    Free PMC article.
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Clara Chen, Rahul Dhanda, +2 authors, Debra A Patt.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918    Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
The application of Oncotype DX in early-stage lymph-node-positive disease.
Sarika Jain, William J Gradishar.
Curr Oncol Rep, 2014 Jan 21; 16(1). PMID: 24442572
Review.
Oncotype dx results in multiple primary breast cancers.
Michael J Toole, Kelley M Kidwell, Catherine Van Poznak.
Breast Cancer (Auckl), 2014 Jan 24; 8. PMID: 24453493    Free PMC article.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Georgeta Fried, Mor Moskovitz.
Springerplus, 2014 Feb 26; 3. PMID: 24567880    Free PMC article.
Patients' perceptions of gene expression profiling in breast cancer treatment decisions.
Y Bombard, L Rozmovits, +3 authors, D A Marshall.
Curr Oncol, 2014 Apr 26; 21(2). PMID: 24764705    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Michael Marrone, Alison Stewart, W David Dotson.
Genet Med, 2014 Dec 05; 17(7). PMID: 25474343    Free PMC article.
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.
Vanessa B Sheppard, Suzanne C O'Neill, +3 authors, Claudine Isaacs.
Clin Breast Cancer, 2015 Jan 04; 15(2). PMID: 25555816    Free PMC article.
The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Yvonne Bombard, Linda Rozmovits, +3 authors, Deborah A Marshall.
Oncologist, 2015 Mar 10; 20(4). PMID: 25746345    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.
B Jahn, U Rochau, +7 authors, U Siebert.
Springerplus, 2015 Dec 23; 4. PMID: 26693110    Free PMC article.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Keith T Schmidt, Cindy H Chau, Douglas K Price, William D Figg.
J Clin Pharmacol, 2016 May 21; 56(12). PMID: 27197880    Free PMC article.
Review.
How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
Deborah A Marshall, Ken Deal, +3 authors, Maureen Trudeau.
BMJ Open, 2016 Jun 04; 6(6). PMID: 27256091    Free PMC article.
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich.
Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Maura Bríd Cotter, Alex Dakin, +5 authors, Cecily M Quinn.
Virchows Arch, 2017 Jul 15; 471(3). PMID: 28707056
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Impact of Recurrence Score on type and duration of chemotherapy in breast cancer.
K Willemsma, W Yip, +5 authors, C E Simmons.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489257    Free PMC article.